Brief: Poxel Announces Detailed Imeglimin Phase 3 TIMES 1 Results

Poxel SA

18/09/2019 12:14

Sept 18 (Reuters) - POXEL SA  POXEL.PA :
    * JAPANESE NEW DRUG APPLICATION FOR IMEGLIMIN IS TARGETED
FOR 2020
    * FOR TIMES 1 TRIAL'S MAIN SECONDARY ENDPOINT OF DECREASE
FROM
BASELINE IN FASTING PLASMA GLUCOSE (FPG), IMEGLIMIN ACHIEVED
STATISTICAL SIGNIFICANCE (P<0.0001) VERSUS PLACEBO AT WEEK 24
    * TIMES 1 TRIAL DEMONSTRATED ROBUST EFFICACY AND ACHIEVED
STATISTICAL SIGNIFICANCE (P<0.0001) FOR ITS PRIMARY ENDPOINT
    * IMEGLIMIN DATA WERE SHOWN TO BE IN HIGH END OF HBA1C
EFFICACY
RANGE WHEN COMPARED TO DATA RESULTS IN JAPANESE PATIENTS TREATED
WITH SGLT2 AND DPP4 INHIBITORS

Source text for Eikon:  ID:nBw4RlFdsa 
Further company coverage:  POXEL.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))